# SLC49A4

## Overview
The SLC49A4 gene encodes the protein solute carrier family 49 member 4, also known as disrupted in renal carcinoma 2 (DIRC2), which is a transmembrane protein functioning as an H+-driven lysosomal pyridoxine (vitamin B6) exporter. This protein is integral to the regulation of pyridoxine homeostasis within cells, facilitating the transport of pyridoxine from lysosomes to the cytosol. DIRC2 is ubiquitously expressed across various human tissues, with notable expression in the placenta, brain, and heart, and plays a critical role in maintaining cellular metabolism and function by preventing excessive lysosomal accumulation of pyridoxine (Akino2022Disrupted). The gene's disruption has been linked to several forms of cancer, including renal cell carcinoma, highlighting its significance in cellular health and disease (Phan2024An).

## Function
The SLC49A4 gene encodes a protein known as disrupted in renal carcinoma 2 (DIRC2), which functions as an H+-driven lysosomal pyridoxine (vitamin B6) exporter. This protein plays a crucial role in the transport of pyridoxine from lysosomes to the cytosol, thereby regulating cellular pyridoxine storage and maintaining pyridoxine homeostasis (Akino2022Disrupted). DIRC2 is expressed ubiquitously across various human tissues, with higher expression levels observed in the placenta, brain, and heart (Akino2022Disrupted).

The protein operates as an electrogenic transporter, facilitating pyridoxine uptake under acidic conditions that mimic the lysosomal environment. This process is driven by an inwardly directed H+ gradient, and the presence of Cl- ions is necessary for efficient transport (Akino2022Disrupted). The activity of DIRC2 is significant in maintaining cellular pyridoxine levels, which are essential for cellular metabolism and function (Akino2022Disrupted).

In healthy human cells, DIRC2's function in exporting pyridoxine from lysosomes prevents excessive accumulation within these organelles, thus contributing to the regulation of pyridoxine turnover and cytosolic availability (Akino2022Disrupted). This regulation is crucial for various cellular functions, including amino acid metabolism and neurotransmitter synthesis (Akino2022Disrupted).

## Clinical Significance
Mutations and alterations in the expression of the SLC49A4 gene, also known as DIRC2, have been implicated in various forms of cancer. Disruption of SLC49A4 is associated with impaired pyridoxine (vitamin B6) turnover, which may contribute to renal carcinogenesis. This disruption can lead to excessive retention of pyridoxine in lysosomes, reducing its availability in the cytosol and potentially increasing cancer risk (Akino2022Disrupted). The gene has also been linked to familial renal cell carcinoma through a translocation breakpoint involving SLC49A4 (Phan2024An).

In addition to renal cancer, alterations in SLC49A4 expression may be a risk factor for other cancers, including colorectal, lung, and breast cancer, due to its role in vitamin B6 metabolism (Akino2022Disrupted). The gene's expression levels have been found to be lower in certain blood cancer cell lines, suggesting a potential link between low expression and carcinogenesis (Akino2022Disrupted).

SLC49A4 is also associated with drug sensitivity in cancer, with its expression correlating with drug response, although specific conditions related to these alterations are not detailed (Lavoro2023In). Further research is needed to fully understand the clinical implications of SLC49A4 in cancer and other diseases.


## References


[1. (Phan2024An) Michael Phan, Maria A. Gomes, Victoria Stinnett, Laura Morsberger, Nicole L. Hoppman, Kathryn E. Pearce, Kirstin Smith, Brian Phan, Liqun Jiang, and Ying S. Zou. An integrated approach including crispr/cas9-mediated nanopore sequencing, mate pair sequencing, and cytogenomic methods to characterize complex structural rearrangements in acute myeloid leukemia. Biomedicines, 12(3):598, March 2024. URL: http://dx.doi.org/10.3390/biomedicines12030598, doi:10.3390/biomedicines12030598. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/biomedicines12030598)

[2. (Lavoro2023In) Alessandro Lavoro, Luca Falzone, Barbara Tomasello, Giuseppe Nicol√≤ Conti, Massimo Libra, and Saverio Candido. In silico analysis of the solute carrier (slc) family in cancer indicates a link among dna methylation, metabolic adaptation, drug response, and immune reactivity. Frontiers in Pharmacology, June 2023. URL: http://dx.doi.org/10.3389/fphar.2023.1191262, doi:10.3389/fphar.2023.1191262. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fphar.2023.1191262)

[3. (Akino2022Disrupted) Shogo Akino, Tomoya Yasujima, Takahiro Yamashiro, and Hiroaki Yuasa. Disrupted in renal carcinoma 2 (dirc2/slc49a4) is an h+-driven lysosomal pyridoxine exporter. Life Science Alliance, 6(2):e202201629, December 2022. URL: http://dx.doi.org/10.26508/lsa.202201629, doi:10.26508/lsa.202201629. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.26508/lsa.202201629)